Abiopharma

New Form SCHEDULE 13G - CULLEN/FROST BANKERS, INC. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000093751-26-000226 <b>Size:</b> 8 KB

New Form SCHEDULE 13G/A - LKQ CORP <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000895421-26-000155 <b>Size:</b> 8 KB

New Form SCHEDULE 13G - Core Natural Resources, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000093751-26-000225 <b>Size:</b> 9 KB

(99% Neutral) ANTERO MIDSTREAM CORP (AM) Announces Regulatory Update

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

New Form SCHEDULE 13G - COMPASS MINERALS INTERNATIONAL INC <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000093751-26-000224 <b>Size:</b> 8 KB

(30% Negative) SAGIMET BIOSCIENCES INC. (SGMT) Reports Q2 2026 Financial Results

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001193125-26-218423 <b>Size:</b> 662 KB

(10% Negative) XILIO THERAPEUTICS, INC. (XLO) Reports Q2 2026 Financial Results

CoyaTherapeutics - Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001918704-26-012715 <b>Size:</b> 663 KB

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001918704-26-012714 <b>Size:</b> 663 KB

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001193125-26-218420 <b>Size:</b> 702 KB